Daniel specialises in advising and representing national and international clients in the life sciences sector. His focus is, among others, on all areas of pharmaceutical law, medical device law, pharmaceutical-advertising law, unfair competition law, and trademark law.

 

For more than 10 years, he has been coordinating and supervising disputes concerning competition law and trademark law for his clients and has, besides his specific focus on litigation, also longstanding experience in advising clients on regulatory and compliance matters, particularly, in the aforementioned areas of law. In context with managing litigation and advising his clients, Daniel is characterised by a strong client focus and his ability to find appropriate and efficient solutions to legal problems.

显示完整简历 隐藏完整简历

最新新闻和观点

纠纷和调查

The Traffic Light Coalition agrees to the legalisation of cannabis products as outlined in the new Coalition Agreement

2021年12月3日
Briefing

作者 Dr. Daniel Tietjen

点击此处了解更多
人工智能与机器学习

Artificial Intelligence Act (AIA) - Legal uncertainty for medical device manufacturers

2021年11月30日
Briefing

作者 Dr. Daniel Tietjen 以及 Dr. Niclas von Woedtke, MBA (Kellogg/ WHU)

点击此处了解更多
纠纷和调查

Current plans of the Traffic Light Coalition to possibly legalise cannabis products

2021年10月26日
Briefing

作者 Dr. Daniel Tietjen

点击此处了解更多
数字医疗

When Health and Technology meet Law – Digital Health @ Taylor Wessing

2021年4月29日
Briefing

作者

点击此处了解更多

与我会面: